Illumina (ILMN) said Tuesday that it will be reimbursed $2,989.55 by the Centers for Medicare and Medicaid Services for each of its TruSight genomic profiling tests.
The company said the reimbursement became effective Jan. 1.
Illumina said its TruSight Oncology Comprehensive test is approved as a companion diagnostic to identify patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase gene fusions, and who may benefit from Bayer's cancer drug VITRAKVI.
Price: 141.67, Change: +0.01, Percent Change: +0.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments